We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Recursion Pharmaceuticals (RXRX - Free Report) closed the most recent trading day at $3.06, moving -5.12% from the previous trading session. This change lagged the S&P 500's daily loss of 1.62%. Meanwhile, the Dow experienced a drop of 1.87%, and the technology-dominated Nasdaq saw a decrease of 1.98%.
Shares of the biotechnology company witnessed a gain of 2.22% over the previous month, trailing the performance of the Medical sector with its gain of 5.04%, and outperforming the S&P 500's loss of 0.03%.
The investment community will be closely monitoring the performance of Recursion Pharmaceuticals in its forthcoming earnings report. It is anticipated that the company will report an EPS of -$0.25, marking a 39.02% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $11.99 million, down 37.64% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.99 per share and revenue of $54.08 million, indicating changes of +31.25% and -27.59%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Recursion Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.99% upward. Recursion Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 155, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX - Free Report) closed the most recent trading day at $3.06, moving -5.12% from the previous trading session. This change lagged the S&P 500's daily loss of 1.62%. Meanwhile, the Dow experienced a drop of 1.87%, and the technology-dominated Nasdaq saw a decrease of 1.98%.
Shares of the biotechnology company witnessed a gain of 2.22% over the previous month, trailing the performance of the Medical sector with its gain of 5.04%, and outperforming the S&P 500's loss of 0.03%.
The investment community will be closely monitoring the performance of Recursion Pharmaceuticals in its forthcoming earnings report. It is anticipated that the company will report an EPS of -$0.25, marking a 39.02% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $11.99 million, down 37.64% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.99 per share and revenue of $54.08 million, indicating changes of +31.25% and -27.59%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Recursion Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.99% upward. Recursion Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 155, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.